Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Mondaycom Ltd — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Mondaycom Ltd trades at $86.87 (market cap $3.57B). The key difference: Mondaycom Ltd is the larger of the two by market cap, and Mondaycom Ltd is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Mondaycom Ltd for 16 Days on average.
| DYN | MNDY | |
|---|---|---|
Market Cap | $2.86B | $3.57B |
Volume | 3,341,579 | 1,023,013 |
Sector | Health | Technology |
52-Week High | $26.78 | $205.24 |
52-Week Low | $14.60 | $58.81 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $2.18B | $2.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Monday.com (MNDY) trades at $84.69, showing minimal daily movement (-0.08%) with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust revenue growth from $1.23B to $1.4B. Recent news highlights AI integration at Elevate '26 conference and inclusion in multiple growth stock lists, while technical indicators show mixed signals with RSI at neutral levels and key support at $83.
The stock presents a compelling growth story with 61.5% analyst buy ratings and a $108.64 consensus target offering 28% upside. However, elevated valuation multiples (P/E 35.83, EV/EBITDA 50.12) and competitive pressures from Meta's enterprise software push pose risks. Net cash flow turned negative in 2026 (-$737M) despite strong operating performance, requiring monitoring of capital allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
